Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Rang în acțiuni #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Preț acțiune
$62.26
Ultima sincronizare: 2026-09-22
Capitalizare de piață
$127.18B
Schimbare (1 zi)
-0.78%
Schimbare (1 an)
38.63%
Țară
US
Tranzacționează Bristol-Myers Squibb Company (BMY)

Categorie

Venituri pentru Bristol-Myers Squibb Company (BMY)
Venituri în Jun 2026 TTM: $49.19B
Conform celor mai recente rapoarte financiare ale Bristol-Myers Squibb Company, venitul actual al companiei (TTM) este $49.19B. În anul 2024, compania a avut un venit de $48.30B o creștere față de venitul din anul 2023, care a fost de $45.01B. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Bristol-Myers Squibb Company din 2000 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
2026 (TTM) $49.19B 2.06%
2025 $48.19B -0.22%
2024 $48.30B 7.32%
2023 $45.01B -2.50%
2022 $46.16B -0.49%
2021 $46.39B 9.09%
2020 $42.52B 62.62%
2019 $26.15B 15.89%
2018 $22.56B 8.59%
2017 $20.78B 6.94%
2016 $19.43B 17.31%
2015 $16.56B 4.29%
2014 $15.88B -3.09%
2013 $16.39B -7.01%
2012 $17.62B -17.05%
2011 $21.24B 9.03%
2010 $19.48B 3.59%
2009 $18.81B -8.69%
2008 $20.60B 6.46%
2007 $19.35B 8.00%
2006 $17.91B -6.73%
2005 $19.21B -0.89%
2004 $19.38B -7.25%
2003 $20.89B 15.32%
2002 $18.12B -6.71%
2001 $19.42B 6.63%
2000 $18.22B 0.00%
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
$79.67B 61.97%
US
$97.93B 99.10%
US
$64.39B 30.90%
US
$77.52B 57.60%
CH
$66.40B 35.00%
US